Deposition of fibrillar aggregates of the ␤-amyloid peptide (A␤) is a key pathologic feature during the early stage of Alzheimer's disease. The initial neuronal responses to A␤ in cortical circuits and the regulation of A␤-induced signaling remain unclear. In this study, we found that exposure of cortical slices to A␤ 1-42 or A␤ 25-35 induced a marked increase in the activation of protein kinase C (PKC) and Ca 2؉ /calmodulin-dependent kinase II (CaMKII), two enzymes critically involved in a variety of cellular functions. Activation of M1 muscarinic receptors, but not nicotinic receptors, significantly inhibited the A␤ activation of PKC and CaMKII. Increasing inhibitory transmission mimicked the M1 effect on A␤, whereas blocking GABA A receptors eliminated the M1 action. Moreover, electrophysiological evidence shows that application of A␤ to cortical slices induced action potential firing and enhanced excitatory postsynaptic currents, whereas muscarinic agonists potently increased inhibitory postsynaptic currents. These results suggest that A␤ activates PKC and CaMKII through enhancing excitatory activity in glutamatergic synaptic networks. Activation of M1 receptors inhibits A␤ signaling by enhancing the counteracting GABA ergic inhibitory transmission. Thus the muscarinic reversal of the A␤-induced biochemical and physiological changes provides a potential mechanism for the treatment of Alzheimer's disease with cholinergic enhancers.
Deposition of fibrillar aggregates of the ␤-amyloid peptide (A␤) is a key pathologic feature during the early stage of Alzheimer's disease. The initial neuronal responses to A␤ in cortical circuits and the regulation of A␤-induced signaling remain unclear. In this study, we found that exposure of cortical slices to A␤ or A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] induced a marked increase in the activation of protein kinase C (PKC) and Ca 2؉ /calmodulin-dependent kinase II (CaMKII), two enzymes critically involved in a variety of cellular functions. Activation of M1 muscarinic receptors, but not nicotinic receptors, significantly inhibited the A␤ activation of PKC and CaMKII. Increasing inhibitory transmission mimicked the M1 effect on A␤, whereas blocking GABA A receptors eliminated the M1 action. Moreover, electrophysiological evidence shows that application of A␤ to cortical slices induced action potential firing and enhanced excitatory postsynaptic currents, whereas muscarinic agonists potently increased inhibitory postsynaptic currents. These results suggest that A␤ activates PKC and CaMKII through enhancing excitatory activity in glutamatergic synaptic networks. Activation of M1 receptors inhibits A␤ signaling by enhancing the counteracting GABA ergic inhibitory transmission. Thus the muscarinic reversal of the A␤-induced biochemical and physiological changes provides a potential mechanism for the treatment of Alzheimer's disease with cholinergic enhancers.
The 40 -42-amino acid ␤-amyloid peptide (A␤) 1 is a major constituent of senile plaques (1), extracellular protein aggregates that are used as a histopathological hallmark for the diagnosis of Alzheimer's disease (AD). Emerging evidence has suggested that A␤ makes a direct contribution to the pathogenesis of AD (2, 3) . A␤ peptides are produced by the cleavage of ␤-amyloid precursor protein (APP) (4) . Mutations in the APP gene increases the rate of cleavage, thereby leading to the overproduction of A␤ (5, 6) . Transgenic mice overexpressing mutant APP genes exhibit AD-like A␤ deposits and cognition impairments (7) (8) (9) . In vitro studies in cell lines and cultured neurons show that fibrillar A␤ is neurotoxic at high concentrations (10, 11) , and most strikingly, A␤ exposure renders neurons more vulnerable to excitatoxicity (12, 13) . Although intensive efforts have been concentrated on factors affecting A␤ production, aggregation, and metabolism (14, 15) , little is known about the earliest biochemical and physiological changes in neurons in response to the subtoxic concentrations of A␤, which may be critical for subsequent neurodegenerative changes and the factors that can regulate the A␤-initiated signaling.
In addition to A␤ deposits, a prominent feature of AD is the degeneration of basal forebrain cholinergic neurons and ensuing deficient cholinergic functions in their target areas including cortex and hippocampus (16 -18) . Despite an improved understanding of the critical role of the cholinergic system in normal cognition and dementia (19, 20) , it has been largely unclear how cholinergic deficits and A␤ accumulation might be related to each other. Previous evidence suggests that A␤ can induce cholinergic hypofunction independently of apparent neurotoxicity (21) , whereas activation of muscarinic receptors can inhibit the generation of amyloidogenic A␤ (22, 23) , indicative of a reciprocal negative regulation between them.
Here we report that treatment of cortical slices with A␤ led to a rapid increase in the activation of protein kinase C (PKC) and Ca 2ϩ /calmodulin-dependent kinase II (CaMKII), and this effect was dependent on A␤-induced excitation of glutamatergic synapses and ensuing Ca 2ϩ influx. Furthermore, the A␤ signaling was selectively down-regulated by the activation of muscarinic receptors through a mechanism involving enhanced GABAergic inhibition. Given the key roles of PKC and CaMKII in regulating a wide range of neuronal functions from synaptic plasticity to cell survival (24, 25) , their strong activation by A␤ could interfere with these critical processes and thereby might contribute to cognitive deficits in AD. The ability of muscarinic receptors to block the A␤ signaling provides one potential mechanism supporting the notion that enhancing cholinergic transmission could be an effective therapeutic strategy in AD treatment (26, 27) .
MATERIALS AND METHODS
Western Blot Analysis-Young adult (3-5 weeks postnatal) rat slices containing frontal cortex were prepared as previously described (28, 29) . All of the experiments were carried out according to the Yroval of State University of New York at Buffalo Animal Care Committee. In brief, the rats were anesthetized by inhaling 2-bromo-2-chloro-1,1,1-trifluoroethane (1 ml/100 g; Sigma) and decapitated; the brains were quickly removed, iced, and then blocked for slicing. The blocked tissue was cut in 300 -400-m slices with a Vibrotome while being bathed in a low Ca 2ϩ (100 M), HEPES-buffered salt solution (140 mM sodium isethionate, 2 mM KCl, 4 mM MgCl 2 , 0.1 mM CaCl 2 , 23 mM glucose, 15 mM HEPES, 1 mM kynurenic acid, pH 7.4, osmolarity ϭ 300 -305). The slices were then incubated for 1 h at room temperature (20 -22°C) in a NaHCO 3 -buffered saline bubbled with 95% O 2 , 5% CO 2 (126 mM NaCl, 2.5 mM KCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 26 mM NaHCO 3 , 1.25 mM NaH 2 PO 4 , 10 mM glucose, 1 mM pyruvic acid, 0.05 mM glutathione, 0.1 mM N G -nitro-L-arginine, 1 mM kynurenic acid, pH 7.4; osmolarity ϭ 300 -305). All of the reagents were obtained from Sigma.
For detecting activated PKC, a phospho-PKC (pan) antibody that recognizes PKC␣, ␤ I , ␤ II , ⑀, , and ␦ isoforms only when phosphorylated at a carboxyl-terminal residue homologous to Ser 660 of PKC␤ II was used in the Western blot analysis. Activated CaMKII was detected with an antibody recognizing the Thr 286 -phosphorylated CaMKII. After incubation, the slices were transferred to boiling 1% SDS and homogenized immediately. Insoluble material was removed by centrifugation (13,000 ϫ g for 10 min), and the protein concentration for each sample was measured. To minimize slice variations, pairs of coronal sections were compared. Equal amounts of protein from slice homogenates were separated on 7.5% acrylamide gels and transferred to nitrocellulose membranes. The blots were blocked with 5% nonfat dry milk for 1 h at room temperature. Then the blots were incubated with the phospho-PKC (pan) antibody (Cell Signaling, 1:2000) or the anti-Thr 286 -phosphorylated CaMKII antibody (Promega, 1:2,000) for 1 h at room temperature. After being rinsed, the blots were incubated with horseradish peroxidase-conjugated anti-rabbit antibodies (Amersham Biosciences; 1:2000) for 1 h at room temperature. Following three washes, the blots were exposed to the enhanced chemiluminescence substrate. Then the blots were stripped for 1 h at 50°C followed by saturation in 5% nonfat dry milk and incubated with a PKC antibody (Santa Cruz . The stocks were thawed and diluted immediately prior to use. The ␤-amyloid peptide A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , the control peptide containing the reverse sequence A␤ , the full-length peptide A␤ , A␤ , and the control peptide containing the reverse sequence A␤ 40 -1 were obtained from Sigma. A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and A␤ were resuspended in sterile distilled water at a concentration of 2 mM and incubated at 37°C for 1 h to allow fibril formation (30) . A␤ , A␤ , and A␤ 40 -1 were resuspended in 50% phosphate-buffered saline at a concentration of 1.5 mg/ml and incubated at 37°C for 4 -7 days to allow fibril formation (31) .
Protein Kinase Assay-After incubation, the brain slices were lysed in cold lysis buffer (1% Triton X-100, 5 mM EDTA, 10 mM Tris, 50 mM NaCl, 30 mM Na 4 P 2 O 7 ⅐10H 2 O, 50 mM NaF, 0.1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, Complete protease inhibitors from Roche Applied Science) on ice for 30 min. The brain lysates were centrifuged and ultracentrifuged, and PKC was immunoprecipitated with mouse monoclonal anti-PKC␣␤␥ (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h, followed by the addition of 50 l of protein A-Sepharose beads and incubation for 1 h at 4°C. The beads were pelleted by centrifugation and washed three times with lysis buffer and three times with kinase buffer (50 mM Tris-HCl, pH 7.5, 5 mM MgCl 2 ) and then resuspended in 30 l of kinase buffer. In vitro kinase activity was measured in the PKC immunoprecipitates using myelin basic protein as substrate. The assay was initiated by the addition of 1 l of [␥-32 P]ATP (10 mCi/ml), 4 l of ATP (100 M), and 1 l of myelin basic protein (5 mg/ml), continued for 20 min at room temperature, and stopped by boiling samples in SDS/PAGE sample buffer. The samples were loaded onto a 20% polyacrylamide gel and subjected to electrophoresis. The gels were vacuum-dried and exposed to Biomax film. The kinase activity was quantified by PhosphorImager.
Electrophysiological Recordings in Slices-To evaluate the regulation of neuronal excitability by A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in frontal cortical slices, the whole cell current clamp recordings were used with patch electrodes (5-9 M⍀) filled with the following internal solution 60 mM K 2 SO 4 , 60 mM N-methyl-D-glucamine, 40 mM HEPES, 4 mM MgCl 2 , 5 mM 1,2-bis(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid (BAPTA), 12 mM phosphocreatine, 2 mM Na 2 ATP, 0.2 mM Na 3 GTP, 0.1 mM leupeptin, pH 7.2-7.3 (osmolarity ϭ 265-270). For the measurement of spontaneous excitatory postsynaptic currents (sEPSCs) in slices, the whole cell voltage clamp recordings were used with the following internal solution: 130 mM cesium methanesulfonate, 10 mM CsCl, 4 mM NaCl, 10 mM HEPES, 1 mM MgCl 2 , 5 mM EGTA, 12 mM phosphocreatine, 5 mM MgATP, 0.2 mM Na 3 GTP, 0.1 mM leupeptin, pH 7.2-7.3 (osmolarity ϭ 265-270). The GABA A receptor antagonist bicuculline (10 M) was added to the recording solution to block the inhibitory transmission. For the measurement of spontaneous inhibitory postsynaptic currents (sIPSCs), the whole cell voltage clamp internal solution contained 100 mM CsCl, 30 mM N-methyl-D-glucamine, 10 mM HEPES, 1 mM MgCl 2 , 4 mM NaCl, 5 mM EGTA, 12 mM phosphocreatine, 2 mM MgATP, 0.2 mM Na 3 GTP, 0.1 mM leupeptin, pH 7.2-7.3 (265-270 mosmol/liter). The AMPA/KA receptor antagonist CNQX (10 M) and NMDA receptor antagonist D(Ϫ)-2-amino-5-phosphonopetanoic acid (25 M) were added to the recording solution to block glutamate transmission. The slice (300 m) was placed in a perfusion chamber attached to the fixed stage of an upright microscope (Olympus) and submerged in continuously flowing oxygenated artificial cerebrospinal fluid. The cells were visualized with a 40ϫ water immersion lens and illuminated with near infrared light, and the image was detected with an infrared-sensitive CCD camera. A Multiclamp 700A amplifier (Axon Instruments, Union City, CA) was used for these recordings. Tight seals (2-10 G⍀) from visualized pyramidal neurons were obtained by applying negative pressure. The membrane was disrupted with additional suction, and the whole cell configuration was obtained. The access resistances ranged from 13 to 18 M⍀ and were compensated 50 -70%. The cells were held at Ϫ70 mV for the recording of spontaneous EPSCs or IPSCs. The Mini Analysis Program (Synaptosoft, Leonia, NJ) was used to analyze synaptic activity. Synaptic currents of 1 min (200 -1000 events) under each different treatment were used for analysis. Statistical comparisons of the synaptic currents were made using the Kolmogorov-Smirnov (K-S) test.
RESULTS

Exposure of Cortical Slices to A␤ Increased PKC and CaMKII
Activation in a Time-and Dose-dependent Manner-To identify possible early cellular responses to A␤ treatment that precede cell death, we examined the effect of A␤ peptides on the activation of two important serine/threonine kinases, PKC and CaMKII, in cortical slices. Because the catalytic competence of many PKC isozymes depends on autophosphorylation at the carboxyl terminus on a conserved residue (32), a phosphospecific pan PKC antibody that detects PKC isoforms only when phosphorylated at this residue was used to detect activated PKC. CaMKII is autophosphorylated at Thr 286 when the enzyme is activated in the presence of Ca 2ϩ /calmodulin, leading to the appearance of a sustained Ca 2ϩ -independent activity (33, 34); thus an anti-Thr 286 -phosphorylated CaMKII antibody was used to detect activated CaMKII. A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , which represents the biologically active region of A␤ (35) (36) (37) , was aged to produce aggregated A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Application of aged A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (10 M) to cortical slices induced a marked increase in the activated PKC and CaMKII. The dose dependence of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -induced PKC and CaMKII activation is shown in Fig. 1 (A and B) . A small effect could be detected following a 10-min exposure to low concentrations of aged A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (0.1-1 M), and a saturating effect was seen at 10 M of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . The total PKC and CaMKII levels exhibited no change with the A␤ 25-35 treatment (Fig. 1A) . Quantification data exhibited a 5.2 Ϯ 1.2-fold increase of PKC (n ϭ 12, p Ͻ 0.001, ANOVA) and a 6.2 Ϯ 1.2-fold increase of CaMKII (n ϭ 12, p Ͻ 0.001, ANOVA) following a 10-min exposure to aged A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (10 M ;  Fig. 1B) . Similarly, the full-length fibrillar A␤ peptide, A␤ , also induced a potent increase in the activated PKC and CaMKII. The dose dependence of A␤ 1-42 -induced PKC and CaMKII activation is shown in Fig. 1C . A small effect was detectable following a 10-min exposure to 0.1 M of aged A␤ , and a saturating effect was observed at 1 M of A␤ . Quantification data exhibited a 5.0 Ϯ 1.0-fold increase of PKC (n ϭ 4, p Ͻ 0.001, ANOVA) and a 6.1 Ϯ 1.1-fold increase of CaMKII (n ϭ 4, p Ͻ 0.001, ANOVA) following a 10-min exposure to aged A␤ (1 M; Fig. 1C ). A representative example is shown in Fig. 1C (inset) . These results suggest that A␤ 1-42 is more potent than A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in activating PKC and CaMKII.
The kinetics of A␤-induced activation of PKC and CaMKII was also tested. As demonstrated in Fig. 1 (D-F) , The PKC and CaMKII activation induced by A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (10 M) or A␤ (1 M) showed rapid and transient kinetics, reaching a peak at 10 min and declining to basal levels within 30 -60 min. In contrast to the potent activation of PKC and CaMKII by A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in cortical slices, A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] failed to elicit the effect in striatal slices (n ϭ 5; data not shown). Given such a time and dose dependence of the A␤ effect on PKC and CaMKII activation, the following experiments were performed with a 10-min treatment of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (10 M) or A␤ (1 M) in frontal cortical slices unless otherwise stated.
We then compared the effect of different A␤ peptides on PKC and CaMKII activation. As shown in Fig. 2 (A and B) , the 10-min treatment with unaged A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide (10 M) also induced a significant increase in activated PKC (2.9 Ϯ 0.55-fold, n ϭ 6, p Ͻ 0.01, ANOVA) and CaMKII (3.8 Ϯ 0.78-fold, n ϭ 6, p Ͻ 0.01, ANOVA), but to a lesser extent than aged A␤ 25 p Ͻ 0.001, ANOVA). To confirm the specificity of the action of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , its control peptide containing the reverse sequence A␤ was used to treat cortical slices. As shown in Fig. 2 (A  and B) , the aged control peptide A␤ (10 M) failed to induce the activation of PKC and CaMKII (PKC, 1.1 Ϯ 0.16-fold; CaMKII, 1.05 Ϯ 0.17-fold; n ϭ 6, p Ͼ 0.05, ANOVA).
As shown in Fig. 2C , the 10-min treatment with aged fulllength A␤ 1-42 peptide (1 M) or A␤ 1-40 peptide (1 M), but not the control peptide A␤ 40 -1 (1 M), also induced a significant increase in activated PKC and CaMKII. To further determine the effects of soluble and fibrillar A␤ , we compared the potency of unaged and aged A␤ 1-42 on PKC and CaMKII activation. Soluable A␤ elicited an observable effect at the concentration of 0.1 M, whereas fibrillar A␤ 1-42 as low as 0.01 M produced a detectable effect (Fig. 2D) . These data suggest that both soluable A␤ (in the form of monomers and oligomers) and highly insoluble A␤ 1-42 fibrils are able to activate PKC and CaMKII, and the fibrillar form of A␤ 1-42 is more potent (ϳ10-fold) than the soluable form.
A␤ Induction of PKC and CaMKII Activation Depends on Excitatory Synaptic Transmission and Ca
2ϩ Influx-To reveal the potential mechanisms underlying A␤-induced activation of PKC and CaMKII, we tested the capability of different channel antagonists to block the A␤ signaling. As shown in Fig. 3 (A and  B) , the effect of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ( Among the five subtypes of mAChRs, M1-M5 (38) , all types apart from M5 are expressed in cortical neurons (39, 40) . We then determined the potential mAChR subtype(s) involved in the regulation of A␤ signaling using specific antagonists. As shown in Fig. 4B , in the presence of the M1/M4 antagonist pirenzepine (1-10 M), oxo-M lost the ability to inhibit A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -induced activation of PKC (5.2 Ϯ 1.3-fold, n ϭ 6, p Ͻ 0.001, ANOVA) and CaMKII (6.5 Ϯ 1.45-fold, n ϭ 6, p Ͻ 0.001, ANOVA). On the contrary, the M2 antagonist methoctramine (10 M) did not prevent the oxo-M inhibition of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] activation of PKC (0.99 Ϯ 0.28-fold, n ϭ 6, p Ͼ 0.05, ANOVA) and CaMKII (0.97 Ϯ 0.31-fold, n ϭ 6, p Ͼ 0.05, ANOVA). Similarly, the A␤ 1-42 -induced activation of PKC and CaMKII was also significantly inhibited by oxo-M, and this effect of oxo-M was blocked by pirenzepine (Fig. 4C) . Given the limited selectivity of pirenzepine (ϳ5-fold) for M1 and M4 receptors (41, 42) , we used MT-7, a highly selective (Ͼ10,000-fold) ligand for M1 receptors (43) , to confirm the involvement of M1 receptors. As shown in Fig. 4C, MT-7 (0.1 M) To further analyze the inhibition of A␤ actions by muscarinic stimulation, we pretreated cortical slices with oxo-M for different durations (0, 10, 30, and 60 min) before adding A␤ 1-42 and incubated for 10 min. As shown in Fig. 4D , no matter how long the pretreatment with oxo-M was (0 -60 min), subsequent addition of A␤ failed to induce any further activation of PKC and CaMKII. There was a small activation of PKC and CaMKII during the initial muscarinic stimulation, but the muscarinic action returned to base line after 10 -30 min. These data suggest that the constant presence of muscarinic activation prevents the A␤-initiated signaling. When we pretreated cortical slices with oxo-M and then washed it out to prevent further muscarinic activation, subsequent addition of A␤ 1-42 regained the ability to activate PKC and CaMKII after 20 min (Fig. 4E) . We also performed in vitro kinase assay to confirm that the A␤ activation of PKC can be blocked by muscarinic stimulation. As shown in Fig. 4F , application of aged A␤ (1 M, 10 min) to cortical slices induced a potent increase of PKC catalytic activity, as measured by the phosphorylation of its substrate myelin basic protein (5.2 Ϯ 0.9-fold, n ϭ 4, p Ͻ 0.001, ANOVA), consistent with the results obtained with the PKC phosphospecific antibody. Pretreatment of cortical slices with oxo-M (10 M, 30 min) abolished the A␤ 1-42 -induced activation of PKC with the enzymatic assay (0.98 Ϯ 0.1-fold, n ϭ 4, p Ͼ 0.05, ANOVA).
Muscarinic Receptors Block A␤ Signaling through the Enhancement of GABAergic Inhibitory Transmission-What might account for the muscarinic inhibition of A␤ signaling? Because the A␤ activation of PKC and CaMKII appears to be dependent on the enhanced glutamatergic excitatory synaptic activity (Fig. 3) , muscarinic receptors should attenuate the A␤ effect if they can enhance the counteracting GABAergic inhibitory synaptic activity. We therefore tested the oxo-M effect on A␤ signaling when the GABA system is manipulated. As shown in Fig. 5 (A and B) , application of the GABA A receptor enhancer diazepam (5 M) exerted a similar effect as oxo-M: blocking the A␤ 25-35 -induced activation of PKC (1.2 Ϯ 0.27-fold, n ϭ 6, p Ͼ 0.05, ANOVA) and CaMKII (1.25 Ϯ 0.29-fold, n ϭ 6, p Ͼ 0.05, ANOVA). Moreover, diazepam largely occluded the effect of subsequent oxo-M application (PKC, 1.02 Ϯ 0.26-fold; CaMKII, 0.98 Ϯ 0.28-fold; n ϭ 5, p Ͼ 0.05, ANOVA). To further confirm that the oxo-M suppression of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] signaling is dependent on the muscarinic enhancement of GABAergic inhibition, we blocked GABA A receptor channels with bicuculline (5 M). As shown in Fig. 5 (C and D) , in the presence of bicuculline, oxo-M failed to inhibit A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -induced activation of PKC (5.1 Ϯ 1.4-fold, n ϭ 6, p Ͻ 0.001, ANOVA) and CaMKII (6.1 Ϯ 1.6-fold, n ϭ 6, p Ͻ 0.001, ANOVA). Likewise, diazepam also blocked the A␤ 1-42 -induced activation of PKC and CaMKII (Fig. 5E) , mimicking the inhibitory effect of oxo-M on A␤ 1-42 signaling (Fig.  4E) . Moreover, bicuculline prevented the oxo-M inhibition of A␤ activation of PKC and CaMKII (Fig. 5E ). These data suggest the requirement of GABAergic inhibitory synaptic transmission in the muscarinic regulation of A␤ actions.
To provide more direct evidence for the mechanisms underlying muscarinic inhibition of A␤ signaling, we performed electrophysiological experiments to test the impact of A␤ and oxo-M on excitatory and inhibitory transmission in cortical slices. The synaptic activity of frontal cortical pyramidal neurons in response to A␤ exposure was first examined using whole cell current clamp recordings. As shown in Fig. 6 (A and  B) , bath application of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ( [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (D), and after washing off the peptide (E). Scale bars, 50 pA, 100 ms. F and G, cumulative plots indicating that the distribution of sEPSC amplitude (F) and frequency (G) was reversibly increased by A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in the neuron. H, histograms (means Ϯ S.E.) showing the percentages of increase of sEPSC amplitude (Amp) and frequency (Freq) by A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (n ϭ 8) and A␤ (n ϭ 5). ctl, control.
whole cell voltage clamp recordings show that A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (10 M) or A␤ 1-42 (2 M) caused a marked increase in the frequency and amplitude of sEPSCs. A representative example is shown in Fig. 6 (C-G). As summarized in Fig. 6H , in a sample of neurons examined, A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] increased the mean sEPSC amplitude by 42.9 Ϯ 5.5% (mean Ϯ S.E., n ϭ 8, p Ͻ 0.001, K-S test) and the mean sEPSC frequency by 141.9 Ϯ 39.1% (n ϭ 8, p Ͻ 0.001, K-S test). Similarly, A␤ increased the mean sEPSC amplitude by 40.5 Ϯ 10.2% (n ϭ 5, p Ͻ 0.001, K-S test) and the mean sEPSC frequency by 131.9 Ϯ 30.1% (n ϭ 5, p Ͻ 0.001, K-S test). In contrast to the potent enhancement of sEPSCs, A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] had no effect on sIPSCs (n ϭ 6, data not shown). On the other hand, oxo-M induced a potent increase in the frequency and amplitude of sIPSCs. A representative example is shown in Fig. 7 (A-E). As summarized in Fig. 7F , in a sample of neurons examined, oxo-M increased the mean amplitude of sIPSCs by 52.3 Ϯ 9.3% (mean Ϯ S.E., n ϭ 7, p Ͻ 0.001, K-S test) and the mean frequency of sIPSCs by 256.1 Ϯ 48.4% (n ϭ 7, p Ͻ 0.001, K-S test). Taken together, these results suggest that A␤ exposure activates excitatory synapses in cortical circuits, and muscarinic receptors enhance the counteracting inhibitory transmission, which could lead to the blockade of the A␤ signaling. DISCUSSION 
A␤-induced Signaling in Cortical
Neurons-Since the discovery of the link between A␤ deposits and AD, therapeutic strategies have been aiming at reducing the brain amyloid burden (14, 15) . A␤ is synthesized and secreted by brain cells (44, 45) . The neurotoxicity after prolonged exposure to high concentrations of A␤ has been established in in vitro models (10, 11) . However, accumulation of diffuse deposits of A␤ in the brain is an early event in the development of AD when there is no massive neuronal death, emphasizing the importance of elucidating the initial neuronal responses to A␤ fibrils that precede neurodegeneration. The significance of understanding the physiological roles of A␤ apart from its neurotoxic effects is perhaps more clear in aged APP transgenic mice (46) , where numerous A␤ plaques are seen in cortical and limbic structures; yet deficits in synaptic plasticity and spatial working memory are accompanied by minimal or no loss of presynaptic or postsynaptic elements (47, 48) . Therefore, the A␤-induced dysfunction of cortical and hippocampal neurons, not their death, may be largely responsible for the impairments in learning and memory associated with AD.
Previous studies have found that A␤ administration induced a marked increase in the tyrosine phosphorylation of multiple proteins in nerve cell lines and cortical cultures (49 -51), suggesting that A␤ has the potential to modulate cellular responses to growth factors and extracellular matrix molecules. In this study, we report a rapid and potent activation of two important serine/threonine kinases, PKC and CaMKII, in response to A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , A␤ , and A␤ in cortical slices. The fibrillar A␤ peptides (A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and A␤ ) were shown to be more potent than their soluable forms in eliciting the activation of PKC and CaMKII, whereas the full-length A␤ and A␤ were found to be more potent than A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in this process. The A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] activation of PKC and CaMKII was not found in HEK293 cell lines (data not shown), indicative of the requirement of some neural specific elements in the A␤ action. Because PKC and CaMKII activation could change the phosphorylation state and functional properties of many downstream targets including neurotransmitter receptors, ion channels, presynaptic terminal proteins, and cytoskeletal molecules (52-54), A␤ might modulate a wide variety of neuronal functions ranging from synaptic plasticity and transmitter release to neurite outgrowth via the regulation of PKC and CaMKII.
Mechanisms for A␤ Signaling-One of the major mechanisms for the A␤-induced cell death is calcium overload and disruption of calcium homeostasis (55) . In this study, pharmacological evidence suggests that A␤ activation of PKC and CaMKII is dependent on Ca 2ϩ influx resulting from A␤-induced excitation of glutamatergic synapses, consistent with previous calcium imaging results showing that application of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] to cultured hippocampal neurons caused increases in the intracellular Ca 2ϩ (56) . Several agents that interfere with glutamatergic transmission, including CNQX, MK-801, and TTX, were effective in eliminating or reducing the A␤ activation of PKC and CaMKII, whereas blocking GABAergic transmission with bicuculline was without effect (Fig. 5, C and D) , indicating that the A␤ action specifically required activation of the excitatory network. Following A␤ activation of glutamate synapses, Ca 2ϩ could enter via several routes, including NMDA receptors, VDCCs, and Ca 2ϩ -permeable AMPA/KA receptors. Parallel electrophysiological studies in cortical pyramidal neurons show that application of A␤ induced excitatory postsynaptic potentials and bursts of action potentials, indicating that A␤ elevated the excitability of these glutamatergic projection neurons. Neither AMPA-nor NMDA-evoked currents were significantly affected by A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (data not shown), suggesting a lack of effect of A␤ on postsynaptic glutamate receptor activity. The A␤-induced increase in sEPSC frequency and amplitude confirms that A␤ caused an increase in glutamate release in cortical circuits. Previous studies have shown that A␤ induces Ca 2ϩ influx through VDCCs in cortical neurons and nerve cell lines (57, 58) , activates large, nonselective cation currents in sympathetic and cortical neurons (59, 60) , and inhibits several potassium currents in basal forebrain cholinergic neurons (61) . Thus the A␤-induced alteration of cellular ionic activity through interaction with existing channels or de novo channel formation (62) might be one of the key mechanisms underlying the A␤ activation of neuronal excitability.
Regulation of A␤ Signaling by Muscarinic Receptors-Given the strong activation of PKC and CaMKII by fibrillar A␤, it is important to know what can potentially modulate this signaling. Our data suggest that activation of muscarinic receptors potently down-regulated the A␤ action, and this effect was specific for M1 receptors. Furthermore, A␤ lost the ability to activate PKC and CaMKII as long as there was constant M1 receptor activation. About 20 min after M1 receptors were inactivated, the ability of A␤ to activate PKC and CaMKII recovered. Therefore, activation of muscarinic receptors will not only modify APP processing and inhibit A␤ production (22, 23, 63) but also suppress A␤ functioning (the present study). The cholinergic deficiency in AD brains could lead to the loss of this negative regulation of amyloidogenic A␤, which in turn could impair M1 signal transduction (64, 65) and inhibit ACh synthesis and release (66, 67) , aggravating further the cholinergic hypofunction (21) . Because these "vicious cycles" could potentially be inhibited by M1 agonists, it suggests that enhancing M1 signaling is a promising point of pharmacological intervention in the treatment of AD (68, 69) .
Mechanisms for Muscarinic Regulation of A␤ SignalingPrevious studies have shown that activation of muscarinic receptors increases the excitability of cortical GABAergic interneurons (70, 71) . Because the A␤ activation of PKC and CaMKII was dependent on enhanced excitatory glutamatergic transmission, we postulated that enhancing the GABAergic inhibitory synaptic activity may account for the muscarinic inhibition of A␤ signaling. Both pharmacological and electrophysiological evidence supports this hypothesis. Several manipulations that interfere with GABA transmission, such as enhancing postsynaptic responses to GABA with diazepam or blocking GABA A receptor functions with bicuculline, were effective in mimicking or blocking the muscarinic inhibition of A␤ signaling, respectively. Moreover, muscarinic agonists potently increased inhibitory postsynaptic currents recorded in pyramidal neurons of frontal cortex. By potentiating GABA inhibition to counteract the elevated glutamate excitation elicited by A␤ exposure, muscarinic receptors not only abrogated the A␤ activation of PKC and CaMKII but also can potentially suppress the A␤-induced susceptibility to excitatoxicity in cortical circuits.
